Skip navigation
Please use this identifier to cite or link to this item:
Files in This Item:
File SizeFormat 
v99n8a16.pdf119,72 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCerqueira, Daniela Mpt_BR
dc.contributor.authorAmorim, Regina MSpt_BR
dc.contributor.authorSilva, Ruiter Rpt_BR
dc.contributor.authorCamara, Geni NLpt_BR
dc.contributor.authorBrígido, Marcelo de Macedopt_BR
dc.contributor.authorMartins, Cláudia RFpt_BR
dc.identifier.citationMem. Inst. Oswaldo Cruz,v.99,n.8,p.877-882,2004pt_BR
dc.description.abstractIn the context of universal access to antiretroviral therapy, the surveillance of human immunodeficiency virus type 1 (HIV-1) genetic diversity and resistance becomes pivotal. In this work our purpose was to describe the genetic variability; prevalence of drug-resistance mutations; and genotypic resistance profiles in HIV-1 infected individuals under antiretroviral treatment, from the Federal District, Brasília, Central Brazil. The entire viral protease and codons 19 to 234 of the reverse transcriptase gene from 45 HIV-1 isolates were amplified and sequenced for subtyping and genotyping. By phylogenetic analysis, 96% of the samples clustered with subtype B and the remaining 4% with HIV-1 subtype F sequences. One major protease inhibitor resistance-associated mutation, I50V, was detected in 38% of the samples. Minor mutations were also found at the protease gene: L10I/V (7%), K20M (2%), M36I (11%), L63P (20%), A71T (2%), and V77I (7%). Many mutations associated with reduced susceptibility to nucleoside or non-nucleoside reverse transcriptase inhibitors were detected: M41L (11%), E44D (4%), D67N (11%), T69D (2%), K70R (11%), L74V (2%), L100I (4%), K103N (18%), V118I (9%), Y181C (11%), M184V (18%), G190A (4%), T215Y (4%), and K219E (4%). This study has shown that 84% of the studied population from the Federal District, showing evidences of therapy failure, presented viral genomic mutations associated with drug resistance. The main antiretrovirals to which this population showed resistance were the PI amprenavir (38%), the NNRTIs delavirdine, nevirapine (31%), and efavirenz (24%), and the NRTIs lamivudine (18%), abacavir, and zidovudine (13%).pt_BR
dc.publisherInstituto Oswaldo Cruz, Ministério da Saúdept_BR
dc.rightsAcesso Abertopt_BR
dc.titleAntiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazilpt_BR
dc.subject.keywordhuman immunodeficiency virus type 1 (HIV-1)pt_BR
dc.subject.keywordantiretroviral resistancept_BR
dc.subject.keywordreverse transcriptasept_BR
Appears in Collections:Uso interno - em processamento

Show simple item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/26148/statistics">

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.